1.51908
LiChrospher® 100 RP-18 endcapped (5 µm) HPLC Columns
L x I.D. 125 mm x 4.6 mm LiChroCART™ HPLC cartridge, manuCART™ holder required for use
Synonyme(s) :
TM=["LiChrospher"] C18 TM=["LICHROCART"] cartridge for HPLC
Sélectionner une taille de conditionnement
| Conditionnement | Référence | Disponibilité | Prix |
|---|---|---|---|
| 1 unit | Veuillez contacter notre Service Clients pour connaître la disponibilité de ce produit. | 1 040,00 $ |
A propos de cet article
1 040,00 $
Nom du produit
LiChrospher® 100 RP-18 endcapped (5µm) LiChroCART™ 125-4.6, suitable for HPLC
material
stainless steel column
agency
suitable for USP L1
product line
LiChrospher®
feature
endcapped
packaging
1 ea of
extent of labeling
21.6% Carbon loading
parameter
250 bar pressure, 60 °C max. temp.
technique(s)
HPLC: suitable, mass spectrometry (MS): suitable (Low - Medium)
column L × I.D.
12.5 cm × 4.6 mm
surface area
350 m2/g
matrix
fully porous particle
matrix active group
C18 (RP18), C18 bonding phase
particle size
5 μm
pore size
100 Å pore size
operating pH range
2-7.5
separation technique
reversed phase
storage temp.
no temp limit
General description
Application
- Liquid chromatographic determination of lumacaftor in the presence of ivacaftor and identification of five novel degradation products using high-performance liquid chromatography ion trap time-of-flight mass spectrometry: This study effectively utilizes the Ascentis® Express F5, 2.7 μm HPLC column to analyze complex pharmaceutical mixtures and identify degradation products, demonstrating the column′s high-resolution capabilities and robust performance in pharmaceutical analysis (Özcan et al., 2023).
- Stability-indicating LC-MS/MS and LC-DAD methods for robust determination of tasimelteon and high resolution mass spectrometric identification of a novel degradation product: This research highlights the use of the Ascentis® Express F5 HPLC column in developing stability-indicating methods for the analysis of tasimelteon, underscoring its crucial role in ensuring the quality and safety of pharmaceuticals through advanced analytical techniques (Özcan et al., 2020).
Legal Information
1 of 1
Cet article | |||
|---|---|---|---|
| matrix active group C18 bonding phase | matrix active group C18 bonding phase | matrix active group C18 bonding phase | matrix active group C18 bonding phase |
| particle size 5 μm | particle size 5 μm | particle size 5 μm | particle size 5 μm |
| separation technique reversed phase | separation technique reversed phase | separation technique reversed phase | separation technique reversed phase |
| pore size 100 Å pore size | pore size 100 Å pore size | pore size 100 Å pore size | pore size 100 Å pore size |
| agency suitable for USP L1 | agency suitable for USP L1 | agency suitable for USP L1 | agency suitable for USP L1 |
| product line LiChrospher® | product line LiChrospher® | product line LiChrospher® | product line LiChrospher® |
Still not finding the right product?
Explore all of our products under LiChrospher® 100 RP-18 endcapped (5µm) LiChroCART™ 125-4.6
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Contenu apparenté
Numéro d'article de commerce international
| Référence | GTIN |
|---|---|
| 1519080001 | 04027269356774 |